Geron Corporation (NASDAQ: GERN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
1.34
+0.06+4.69%
Earnings
Up 4.7% — Reported earnings — EPS beat by 39%, revenue beat by 2%.
High confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.10 | Insider Own | 5.39% | Shs Outstand | 641.52M | Perf Week | -7.59% |
| Market Cap | 859.64M | Forward P/E | 16.63 | EPS next Y | 0.08 | Insider Trans | -0.03% | Shs Float | 535.70M | Perf Month | -6.94% |
| Enterprise Value | 796.64M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 13.05% | Perf Quarter | -14.65% |
| Income | -69.00M | P/S | 4.39 | EPS this Y | 79.04% | Inst Trans | - | Short Ratio | 5.01 | Perf Half Y | -12.99% |
| Sales | 196.00M | P/B | 3.75 | EPS next Y | 484.45% | ROA | -13.03% | Short Interest | 69.92M | Perf YTD | 1.52% |
| Book/sh | 0.36 | P/C | 2.74 | EPS next 5Y | - | ROE | -28.90% | 52W High | 2.01 -33.33% | Perf Year | 14.53% |
| Cash/sh | 0.49 | P/FCF | - | EPS past 3/5Y | - | ROIC | -7.77% | 52W Low | 1.04 28.85% | Perf 3Y | -55.48% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 468.77% - | Gross Margin | 86.59% | Volatility | 6.21% 5.63% | Perf 5Y | 3.88% |
| Dividend TTM | - | EV/Sales | 4.06 | EPS Y/Y TTM | 62.96% | Oper. Margin | -19.05% | ATR (14) | 0.08 | Perf 10Y | -49.62% |
| Dividend Ex-Date | - | Quick Ratio | 6.78 | Sales Y/Y TTM | 154.55% | Profit Margin | -35.48% | RSI (14) | 45.97 | Recom | 2.32 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.78 | EPS Q/Q | - | SMA20 | -5.77% | Beta | 0.58 | Target Price | 5.89 |
| Payout | 0.00% | Debt/Eq | 1.11 | Sales Q/Q | 30.00% | SMA50 | 1.44% | Rel Volume | 1.04 | Prev Close | 1.28 |
| Employees | 258 | LT Debt/Eq | 1.03 | Earnings | Aug 05 | SMA200 | -4.21% | Avg Volume | 12.93M | Price | 1.34 |
| IPO Date | Jul 31, 1996 | Option/Short | No / Yes | EPS/Sales Surpr. | 38.61% 2.47% | Net Debt/EBITDA | -4.90 | Volume | 13,458,290 | Change | 4.69% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform | |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral | |
| Feb-27-25 | Reiterated | Barclays | Overweight | $4.00 |
| Feb-26-25 | Downgrade | HC Wainwright & Co. | Buy → Neutral | |
| Oct-22-24 | Reiterated | B.Riley Financial | Buy | |
| Sep-09-24 | Initiated | Leerink | Outperform | |
| Jun-10-24 | Reiterated | Goldman Sachs | Buy | $5.00 |
| Jun-10-24 | Reiterated | Stifel Nicolaus | Hold | |
| Apr-30-24 | Reiterated | Robert W. Baird | $4.50 | |
| Apr-30-24 | Downgrade | Baird | Outperform → Neutral |
Latest News
Aug-04-26
Jul-22-26
Jul-22-2604:01PM
07:00AM
Jul-15-26
Jul-15-2609:00AM
Jul-14-26
Jul-14-2604:26PM
Jul-13-26
Jul-13-2608:00AM
Jul-01-26
Jul-01-2610:11AM
Company
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 196 | 184 | 77 | 0 | 1 | 1 | 0 | 0 | 1 | |
| Cost of Goods Sold Incl. D&A | 26 | 5 | 1 | 0 | 0 | 0 | 50 | 51 | 13 | |
| Gross Profit | 170 | 179 | 76 | 0 | 1 | 1 | -50 | -51 | -12 | |
| Selling, General and Administrative Excl. Other | 155 | 159 | 146 | 69 | 44 | 30 | 27 | 22 | 19 | |
| Research and Development | 74 | 74 | 104 | 125 | 96 | 86 | 51 | 52 | 13 | |
| Other Operating Expense | -23 | 0 | -1 | 0 | -1 | -1 | -51 | -52 | 0 | |
| Operating Income | -37 | -54 | -174 | -194 | -139 | -114 | -77 | -73 | -31 | |
| Interest Expense | 32 | 33 | 19 | 8 | 7 | 4 | 1 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 1 | 18 | 18 | 4 | 2 | 2 | 4 | 4 | |
| Net Income Before Taxes | -69 | -86 | -175 | -184 | -142 | -116 | -76 | -69 | -27 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -69 | -86 | -175 | -184 | -142 | -116 | -76 | -69 | -27 | |
| Net Income From Continuing Operations | -69 | -86 | -175 | -184 | -142 | -116 | -76 | -69 | -27 | |
| Net Income | -69 | -86 | -175 | -184 | -142 | -116 | -76 | -69 | -27 | |
| EPS (Recurring) | -0.10 | -0.13 | -0.27 | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | |
| EPS (Basic, Before Extraordinaries) | -0.10 | -0.13 | -0.27 | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | |
| EPS (Diluted) | -0.10 | -0.13 | -0.27 | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | |
| EBITDA | -38 | -52 | -155 | -175 | -134 | -112 | -77 | -72 | -27 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.57 | 4.79 | 29.70 | — | 922.02 | 400.16 | — | — | 177.00 | |
| Gross Margin | 86.73 | 97.28 | 98.70 | — | 100.00 | 100.00 | — | — | -1,200.00 | |
| Operating Margin | -18.88 | -29.35 | -225.97 | — | -13,900.00 | -11,400.00 | — | — | -3,100.00 | |
| Net Margin | -35.20 | -46.74 | -227.27 | — | -14,200.00 | -11,600.00 | — | — | -2,700.00 | |
| Shares Outstanding | 669 | 667 | 646 | 571 | 381 | 328 | 271 | 190 | 177 | |
| Market Capitalization | 896 | 880 | 2,287 | 1,205 | 922 | 400 | 431 | 258 | 177 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Feb 18 '26 | Option Exercise | 0.00 | 27,500 | 0 | 27,500 | Feb 19 |
| ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | Feb 18 '26 | Sale | 1.94 | 9,855 | 19,119 | 17,645 | Feb 19 |
| LAWLIS V BRYAN | Director | May 09 '25 | Buy | 1.18 | 13,300 | 15,667 | 13,300 | May 13 |
| Samuels Scott Alan | EVP, Chief Legal Officer | Feb 27 '25 | Buy | 1.61 | 15,000 | 24,150 | 26,682 | Mar 03 |
| SCARLETT JOHN A | Chairman, President and CEO | Feb 27 '25 | Buy | 1.76 | 12,500 | 22,063 | 12,500 | Mar 03 |
| Ziegler James | EVP, Chief Commercial Officer | Feb 27 '25 | Buy | 1.60 | 100,000 | 160,000 | 100,000 | Mar 03 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer | Jul 08 '24 | Option Exercise | 1.72 | 1,127,152 | 1,938,702 | 674,348 | Jul 10 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer | Jul 08 '24 | Sale | 4.56 | 674,348 | 3,073,004 | 0 | Jul 10 |
| Feller Faye | EVP, Chief Medical Officer | Jun 10 '24 | Option Exercise | 1.19 | 287,900 | 341,693 | 155,400 | Jun 12 |
| Feller Faye | EVP, Chief Medical Officer | Jun 10 '24 | Sale | 4.63 | 287,900 | 1,334,129 | 0 | Jun 12 |
| Kapur Anil | EVP, Corp Strategy & CCO | Jun 10 '24 | Option Exercise | 1.06 | 421,875 | 447,188 | 421,875 | Jun 12 |
| Kapur Anil | EVP, Corp Strategy & CCO | Jun 10 '24 | Sale | 4.64 | 421,875 | 1,959,609 | 0 | Jun 12 |
| SCARLETT JOHN A | Chairman, President and CEO | Jun 04 '24 | Sale | 4.00 | 600,000 | 2,400,000 | 600,000 | Jun 05 |
| SCARLETT JOHN A | Chairman, President and CEO | Jun 04 '24 | Option Exercise | 2.54 | 600,000 | 1,524,000 | 600,000 | Jun 05 |
| LAWLIS V BRYAN | Director | May 15 '24 | Option Exercise | 1.94 | 35,000 | 67,900 | 35,000 | May 17 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.